← Back to Search

Imaginal Exposure Therapy for Eating Disorders (In-vivo IE II Trial)

N/A
Waitlist Available
Research Sponsored by University of Louisville
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have at least one significant eating disorder related fear.
Must currently meet criteria for anorexia, sub-clinical anorexia, bulimia, or sub-clinical bulimia (using the eating disorder diagnostic scale), OR have met criteria for one of these eating disorders in the last year, OR endorse significant eating disorder fears
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year and 10 weeks
Awards & highlights

In-vivo IE II Trial Summary

This trial will test if a therapy that involves imagining oneself in feared situations can help to ease symptoms of eating disorders and anxiety.

Who is the study for?
This trial is for adults with significant fears related to eating disorders such as anorexia or bulimia, whether currently diagnosed or within the last year. It's not open to those with binge eating disorder, unspecified eating disorders, mania, psychosis, suicidal thoughts, or under 18s.Check my eligibility
What is being tested?
The study is examining if imaginal exposure therapy can help reduce symptoms of anxiety and various eating disorders by having participants face their fears in a controlled environment.See study design
What are the potential side effects?
While the trial involves psychological therapy rather than medication, side effects may include increased anxiety or emotional distress during early stages of treatment as patients confront difficult emotions and memories.

In-vivo IE II Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must have at least one major fear related to your eating disorder.
Select...
You currently have or have had anorexia, bulimia, or related eating disorders in the past year. Or you have significant fears related to eating disorders.

In-vivo IE II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year and 10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Mass Index (BMI) at 1-10 Weeks and at 1 year
EDEQ (Eating Disorder Examination Questionnaire) at 1-10 Weeks and at 1 year
SUDS (Subjective Units of Distress Scale) at 1-10 Weeks and at 1 year

In-vivo IE II Trial Design

1Treatment groups
Experimental Treatment
Group I: Imaginal Exposure SessionExperimental Treatment1 Intervention
All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
imaginal exposure therapy
2017
N/A
~50

Find a Location

Who is running the clinical trial?

University of LouisvilleLead Sponsor
336 Previous Clinical Trials
75,897 Total Patients Enrolled
1 Trials studying Exposure
208 Patients Enrolled for Exposure

Media Library

Imaginal Exposure Therapy Clinical Trial Eligibility Overview. Trial Name: NCT03934697 — N/A
Exposure Research Study Groups: Imaginal Exposure Session
Exposure Clinical Trial 2023: Imaginal Exposure Therapy Highlights & Side Effects. Trial Name: NCT03934697 — N/A
Imaginal Exposure Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03934697 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies in this trial available for participants?

"The information on the clinicaltrials.gov database reveals that this trial is not presently recruiting patients; however, it was initially posted in May 2017 and last updated in October 2022. There are currently 167 other trials actively welcoming participants."

Answered by AI
~5 spots leftby Mar 2025